Sudha Seshadri, MD
Professor
Boston University School of Medicine
Dept of Neurology

MD, All India Institute of Medical Science (AIIMS)
MBBS, Christian Medical College & Hospital
DM, All India Institute of Medical Science (AIIMS)



I have been an investigator at the Framingham Heart Study (FHS) since 1998, leading the clinical neurology and neurogenetics cores since 2005 and currently serve as PI on 9 NIH grants, 5 R01 grants, 3 U01s and a UH2. As a board certified neurologist and Professor of Neurology at the Boston University School of Medicine, I run a Geriatric Memory Disorders and Dementia clinic, supervise a resident general neurology clinic and cover the in-patient, consult and emergency services for one month in each year. I also served as Co-Director of Medical Education for the Neurology Residency Program between 2005 and 2012. I was Director of the neurology segment of the Biology of Disease/ Disease and Therapy course for 2nd year medical students between 2008-2010 and in 2015-16 and continue to teach the Dementia module. I currently spend 75% of my time on research and mentoring within the context of the Framingham study and have served as primary mentor for over 30 physician and non-physician investigators funded by a wide range of grants, national (K23, AAN, AHA) and international (Fulbright, Bettencourt-Schuller, Sidney-Sax etc.).

In my research capacity, I currently lead the clinical neurology and neurogenetics cores at the FHS, where we explore the cumulated and age-specific impacts of a wide variety of genomic and environmental risk factors underlying stroke, dementia and brain aging across 3 generations of participants. This entails undertaking brain MRI, cognitive tests, brain autopsies, biomarker, candidate gene, genome-wide association, sequencing and expression studies. At FHS, my key contributions have included updating the dementia database with improved tracking, review and new classification systems, studying novel biomarkers such as BDNF, NGF and beta-amyloid, and establishing a brain bank program. In addition I play a major role in consolidating, refining and expanding various aspects of the MRI and stroke databases. Further, as lead neurogenetics investigator I have funded whole exome sequencing on over 1300 Framingham Study participants.

My research focuses on 4 interrelated areas: (a) exploring the correlates of subclinical brain aging including establishing norms for brain MRI and cognitive test performance and relating these measures to novel risk factors (such as visceral fat mass), multiple circulating biomarkers and clinical and subclinical indices of vascular and metabolic disease; (b) the epidemiology of stroke and vascular cognitive impairment including the lifetime risk of stroke, cognitive decline and dementia following stroke, the role of parental stroke and midlife risk factors in determining late-life stroke risk and temporal trends in stroke risk over the past 50 years; (c) the epidemiology of dementia and Alzheimer’s disease (AD) including describing the lifetime risk of AD and relating traditional and novel biomarkers (homocysteine, lipids, diabetes, estrogen, bone mineral density, thyroid function, inflammation) to the risk of dementia and AD. I have been especially interested in exploring the role of reversible lifestyle, vascular and metabolic risk factors in determining dementia risk with a special focus on understanding the putative causal pathways and biomarkers, such as leptin and other adipokines, BDNF and other neurotrophic factors, in mediating this risk, and (d) understanding the genomic and epigenetic variation underlying brain aging, stroke, AD and vascular cognitive impairment.

My most significant research contributions have been (i) developing the concept of lifetime risk as applicable to dementia and other chronic diseases, (ii) helping to establish plasma homocysteine as an important risk marker for dementia and AD (including a first author paper in the NEJM in 2002 that has had over 1400 citations), (iii) relating low plasma leptin levels to the risk of dementia and AD (published in JAMA, 2009 as senior author), (iv) describing a novel gene, NINJ2, associated with ischemic stroke (NEJM, 2009 as corresponding author), (v) describing two genes, BIN1 and EXOCL2, associated with Alzheimer disease in the largest, multi-centric genome-wide association study to date (JAMA, 2010 as first author) and identifying novel genes underlying hippocampal volume in healthy adults (Nature Genetics, 2012 as Senior author).

I have over 280 peer-reviewed publications and reviews. I also established, partially fund and coordinate the neurology phenotype working group within the international Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium started in January 2008. This consortium brings together investigators from several of the leading cohort studies, the FHS, the Atherosclerosis Risk in Communities Study (ARIC), the Cardiovascular Health study (CHS), the Rotterdam study, the Age, Gene, Environment Susceptibility- Reykjavik (AGES-Reykjavik) study and the Austrian Study for Prevention of Stroke (ASPS). In my capacity as coordinator of neuroCHARGE, I am also a founding member of the International Genomics of Alzheimer's Project (IGAP) that brings together 4 major European and US groups who are currently the leaders in AD genomics research, am a PI of the Alzheimer Disease Sequencing Project (ADSP) that assesses rare genetic variation underlying PD in over 11,500 persons, a member of the Steering Committee for the International Stroke Genetics Consortium (ISGC) and Chair of the METASTROKE consortium.

A particular emphasis of mine throughout my career has been and will continue to be mentoring younger colleagues at my own institution and around the world towards academic careers. Collectively, my mentees have over 80 first author papers that I mentored published in leading journals including NEJM, Lancet, Nature Genetics, JAMA, JAMA Internal Medicine, JAMA Neurology, Annals of Neurology, Brain, Stroke and Neurology.

Framingham Heart Study



2013 American Academy of Neurology: Fellow
2013-2013 Boston University: Jack Spivack Excellence in Neurosciences Award
2012 American Neurological Association: Fellow


Microgial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium
09/30/2016 - 07/31/2018 (PI)
NIH/National Institute of Neurological D
1UH2NS100605-01

Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer Disease in Framingham Cohorts
09/01/2016 - 05/31/2018 (PI)
NIH/National Institute on Aging
1R01AG054076-01

ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model Systems
09/01/2016 - 05/31/2018 (PI)
NIH/National Institute on Aging
1U01AG052409-01

AD Gene Discovery: Exome Chip, New Endophenotypes & Functional studies in CHARGE
06/01/2016 - 05/31/2018 (PI)
NIH/National Institute on Aging
4R01AG033193-07

CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample
06/15/2014 - 05/31/2018 (PI)
NIH/National Institute on Aging
5U01AG049505-03

An integrated genetic and epigenetic approach to cerebral small vessel disease
04/01/2015 - 03/31/2018 (PI)
University of Texas Health Science Cente NIH NINDS
5R01NS087541-03

Precursors of Stroke Incidence and Prognosis
03/01/2016 - 02/28/2018 (PI)
NIH/National Institute of Neurological D
5R01NS017950-34

MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults
06/01/2016 - 01/31/2018 (Co-PI)
PI: Rhoda Au, PhD
NIH/National Institute on Aging
5R01AG033040-08

Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults
05/15/2015 - 01/31/2018 (PI)
NIH/National Institute on Aging
5R01AG049607-03

Consortium to Study the Genetics of Longevity
06/01/2015 - 06/30/2017 (PI)
Sutter Bay Hospitals dba California Paci NIH NIA
5U19AG023122-10

Showing 10 of 21 results. Show All Results



Yr Title Project-Sub Proj Pubs
2017 Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium 5UH2NS100605-02
2017 Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts 3R01AG054076-02S1
2017 Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults 5R01AG049607-03 7
2017 MRI, Cognitive, Genetic and Biomarker Precursors of AD & Dementia in Young Adults 5R01AG033040-08 24
2017 Precursors of Stroke Incidence and Prognosis 5R01NS017950-34 328
2016 Microglial, Inflammatory and Omics Markers of Cerebral Small Vessel Disease in the CHARGE Consortium 1UH2NS100605-01
2016 ADSP Follow-up in Multi-Ethnic Cohorts via Endophenotypes, Omics & Model Systems 1U01AG052409-01
2016 Temporal Trends, Novel Imaging and Molecular Characterization of Preclinical and Clinical Alzheimer's Disease in the Framingham Cohorts 1R01AG054076-01
2016 Preclinical AD: Correlates of Amyloid, Tau PET and fcMRI in Framingham Gen 3 Young Adults 5R01AG049607-02 7
2016 CHARGE: Identifying Risk & Protective SNV for AD in ADSP Case-control Sample 5U01AG049505-03 6
Showing 10 of 30 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Adams S, Conner S, Himali JJ, Beiser A, Vasan RS, Seshadri S, Pase MP. Vascular risk factor burden and new-onset depression in the community. Prev Med. 2017 Nov 29.View Related Profiles. PMID: 29197532; DOI: 10.1016/j.ypmed.2017.11.022;.
  2. Weinstein G, Zelber-Sagi S, Preis SR, Beiser AS, DeCarli C, Speliotes EK, Satizabal CL, Vasan RS, Seshadri S. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-Aged Adults in the Framingham Study. JAMA Neurol. 2017 Nov 20.View Related Profiles. PMID: 29159396.
  3. McGrath ER, Beiser AS, DeCarli C, Plourde KL, Vasan RS, Greenberg SM, Seshadri S. Blood pressure from mid- to late life and risk of incident dementia. Neurology. 2017 Dec 12; 89(24):2447-2454.View Related Profiles. PMID: 29117954.
  4. Stathopoulou MG, Xie T, Ruggiero D, Chatelin J, Rancier M, Weryha G, Kurth MJ, Aldasoro Arguinano AA, Gorenjak V, Petrelis AM, Dagher G, Dedoussis G, Deloukas P, Lamont J, Marc J, Simmaco M, Schaik RHNV, Innocenti F, Merlin JL, Schneider J, Alizadeh BZ, Ciullo M, Seshadri S, Visvikis-Siest S. A transnational collaborative network dedicated to the study and applications of the vascular endothelial growth factor-A in medical practice: the VEGF Consortium. Clin Chem Lab Med. 2017 Oct 31. PMID: 29087954.
  5. Chibnik LB, Wolters FJ, Bäckman K, Beiser A, Berr C, Bis JC, Boerwinkle E, Bos D, Brayne C, Dartigues JF, Darweesh SKL, Debette S, Davis-Plourde KL, Dufouil C, Fornage M, Grasset L, Gudnason V, Hadjichrysanthou C, Helmer C, Ikram MA, Ikram MK, Kern S, Kuller LH, Launer L, Lopez OL, Matthews F, Meirelles O, Mosley T, Ower A, Psaty BM, Satizabal CL, Seshadri S, Skoog I, Stephan BCM, Tzourio C, Waziry R, Wong MM, Zettergren A, Hofman A. Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium. Eur J Epidemiol. 2017 Oct; 32(10):931-938.View Related Profiles. PMID: 29063414.
  6. Huan T, Chen G, Liu C, Bhattacharya A, Rong J, Chen BH, Seshadri S, Tanriverdi K, Freedman JE, Larson MG, Murabito JM, Levy D. Age-associated microRNA expression in human peripheral blood is associated with all-cause mortality and age-related traits. Aging Cell. 2017 Oct 17.View Related Profiles. PMID: 29044988.
  7. Pase MP, Seshadri S. Author response: Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology. 2017 Oct 03; 89(14):1532-1533. PMID: 28972109.
  8. Pase MP, Westwood AJ, Beiser A, Jain N, DeCarli C, Himali JJ, Auerbach SH, Seshadri S. Author response: Prolonged sleep duration as a marker of early neurodegeneration predicting incident dementia. Neurology. 2017 Oct 03; 89(14):1533.View Related Profiles. PMID: 28972111.
  9. Rannikmäe K, Sivakumaran V, Millar H, Malik R, Anderson CD, Chong M, Dave T, Falcone GJ, Fernandez-Cadenas I, Jimenez-Conde J, Lindgren A, Montaner J, O''Donnell M, Paré G, Radmanesh F, Rost NS, Slowik A, Söderholm M, Traylor M, Pulit SL, Seshadri S, Worrall BB, Woo D, Markus HS, Mitchell BD, Dichgans M, Rosand J, Sudlow CLM. COL4A2 is associated with lacunar ischemic stroke and deep ICH: Meta-analyses among 21,500 cases and 40,600 controls. Neurology. 2017 Oct 24; 89(17):1829-1839. PMID: 28954878.
  10. Lin H, Satizabal C, Xie Z, Yang Q, Huan T, Joehanes R, Wen C, Munson PJ, Beiser A, Levy D, Seshadri S. Whole blood gene expression and white matter Hyperintensities. Mol Neurodegener. 2017 09 18; 12(1):67.View Related Profiles. PMID: 28923099.
Showing 10 of 306 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 306 publications over 24 distinct years, with a maximum of 48 publications in 2015

YearPublications
19891
19911
19942
19951
19971
19991
20002
20015
20024
20033
20046
20052
20068
20079
20085
200913
201014
201118
201222
201324
201431
201548
201643
201742
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

Alzheimer Disease
Epidemiology
GEnetics
Stroke

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Research / Scholarly Mentor
  • Work / Life Integration Mentor
Contact for Mentoring:


72 E. Concord St Robinson (B)
Boston MA 02118
Google Map


Seshadri's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department